New York Clinical Trials Report — June 2026

For New Yorkers exploring opportunities to contribute to medical science, June 2026 presents a dynamic landscape of clinical trials. While 106 new studies have just opened their doors, a significant number of trials are also nearing their enrollment deadlines. In fact, 321 clinical trials across the state are set to close within the next 90 days, creating an urgent window for participation.

This includes 76 trials that are actively seeking healthy volunteers, offering a chance for individuals without specific medical conditions to play a vital role in advancing healthcare. If you've considered participating in research, now is a crucial time to explore these options before they conclude.

New Horizons in Research: Major Trials Launching This Month

New York's research ecosystem is bustling, with 106 new trials opening in June, a notable increase from the 86 that began in May 2026. These new studies span a wide array of conditions and intervention types, including several significant Phase 3 drug trials from major pharmaceutical companies and impactful public health initiatives from leading academic institutions.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron.
• Pfizer is leading an important Phase 3 vaccine trial, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This trial aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants.
• Colgate Palmolive is sponsoring NCT07619729, a Phase 4 study titled "Evaluate the Efficacy of an Oral Health Behavioral Intervention in People With Diabetes." This large-scale study plans for 10,000 participants to assess the impact of a behavioral intervention on dental claims in individuals with Type 2 Diabetes.
• NYU Langone Health is at the forefront of several significant public health initiatives. NCT07656584, "Implementation of Communication Disability Collection and Accommodations in Primary Care Settings," is a multi-site study targeting 126,870 participants to improve communication support in healthcare. Additionally, NCT07665060, "HIV Antibody Increases Following Viral Rebound in People Receiving Antiretroviral Therapy," seeks 6,100 participants to establish a proof-of-concept for rapid viral rebound detection. Another NYU Langone Health study, NCT07631858, "Perspectives About Online Information," will enroll 3,200 participants to understand U.S. adults' views on online prostate cancer information.
• The University of British Columbia is sponsoring NCT07629154, "Smart Discharges for Older Children," an observational multi-country cohort study aiming for 4,000 participants. This research seeks to develop algorithms to identify children at risk of mortality after discharge from sepsis treatment in East Africa.

Conditions and Interventions: A Diverse Research Landscape

The 106 new trials opening this month address a broad spectrum of health concerns. Conditions with the most new research opportunities include:

• Obesity (4 trials)
• Prostate cancer (4 trials)
• Overweight (3 trials)
• Anxiety (3 trials)
• Pneumococcal disease (2 trials)
• Sepsis (2 trials)
• Chronic weight management (2 trials)
• Migraine (2 trials)
• Myopia (2 trials)
• Nephrolithiasis (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 41 of the new studies. Device trials are also prominent with 23 new studies, followed by behavioral interventions with 15. This diversity ensures that research is advancing across various therapeutic approaches.

Geographic Reach: New York City Dominates, Other Regions Expand Access

New York State currently hosts a robust clinical research environment, with 4,437 trials actively recruiting across 199 cities and 2,973 research sites. This month, the majority of new research initiatives are concentrated in the New York City metropolitan area, reflecting its status as a major medical hub. The cities with the most new trials include:

• New York (62 new trials)
• Commack (12 new trials)
• The Bronx (10 new trials)
• Harrison (9 new trials)
• Rochester (9 new trials)
• Uniondale (6 new trials)
• Albany (5 new trials)
• Brooklyn (5 new trials)
• Manhasset (4 new trials)
• Rockville Centre (3 new trials)

While a significant portion of new research is concentrated in New York City, the presence of new trials in Rochester, Albany, and other suburban areas demonstrates a commitment to expanding access to cutting-edge research opportunities throughout the state.

Act Now: Trials Nearing Conclusion

As mentioned, 321 trials are closing within the next 90 days, and individuals with specific health conditions should review these opportunities promptly. Many of these studies focus on critical areas, particularly various forms of cancer. Conditions with trials closing soon include:

• Breast cancer (10 trials)
• Ovarian cancer (6 trials)
• Prostate cancer (6 trials)
• Cancer (5 trials)
• Depression (4 trials)
• Colorectal cancer (4 trials)
• Metastatic breast cancer (3 trials)
• Lung cancer (3 trials)
• Metastatic malignant solid neoplasm (3 trials)
• Acute myeloid leukemia (3 trials)

If you or a loved one are affected by these conditions, exploring these trials before their enrollment window closes could provide access to new treatment options.

Opportunities for Healthy Volunteers and Diverse Participants

For those without a specific medical condition, there are ample opportunities to contribute to medical science. Of the 106 new trials launched this month, 16 are actively seeking healthy volunteers. Statewide, a total of 576 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and prevention efforts.

Clinical trials in New York are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 15 include children as participants, 8 are female-only, and 5 are male-only, ensuring that research benefits diverse demographics. Additionally, 86 of the new trials include older adults, highlighting a focus on the health needs of the aging population.

Academic institutions continue to play a vital role in the state's research ecosystem, with Memorial Sloan Kettering Cancer Center sponsoring 10 of the new trials, followed by Icahn School of Medicine at Mount Sinai with 7, and Northwell Health and NYU Langone Health each sponsoring 6. Industry sponsors are also driving significant research efforts, with 36 new trials sponsored by pharmaceutical companies such as AstraZeneca and Pfizer.

As we move through June, the focus remains on the continued enrollment in these significant new trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across New York.